Authors
Loading...
In vivo approach reveals that targeting ADAM17 suppresses airway inflammation in allergic asthma, indicating potential therapy options.
Jaiswal et al. (2025) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: